PMID- 27109697
OWN - NLM
STAT- MEDLINE
DCOM- 20171116
LR  - 20220408
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 5
IP  - 7
DP  - 2016 Jul
TI  - Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and 
      neck squamous cell carcinomas.
PG  - 1619-28
LID - 10.1002/cam4.718 [doi]
AB  - Identification of novel prognostic biomarkers typically requires a large dataset 
      which provides sufficient statistical power for discovery research. To this end, 
      we took advantage of the high-throughput data from The Cancer Genome Atlas (TCGA) 
      to identify a set of prognostic biomarkers in head and neck squamous cell 
      carcinomas (HNSCC) including oropharyngeal squamous cell carcinoma (OPSCC) and 
      other subtypes. In this study, we analyzed miRNA-seq data obtained from TCGA 
      patients to identify prognostic biomarkers for OPSCC. The identified miRNAs were 
      further tested with an independent cohort. miRNA-seq data from TCGA was also 
      analyzed to identify prognostic miRNAs in oral cavity squamous cell carcinoma 
      (OSCC) and laryngeal squamous cell carcinoma (LSCC). Our study identified that 
      miR-193b-3p and miR-455-5p were positively associated with survival, and 
      miR-92a-3p and miR-497-5p were negatively associated with survival in OPSCC. A 
      combined expression signature of these four miRNAs was prognostic of overall 
      survival in OPSCC, and more importantly, this signature was validated in an 
      independent OPSCC cohort. Furthermore, we identified four miRNAs each in OSCC and 
      LSCC that were prognostic of survival, and combined signatures were specific for 
      subtypes of HNSCC. A robust 4-miRNA prognostic signature in OPSCC, as well as 
      prognostic signatures in other subtypes of HNSCC, was developed using sequencing 
      data from TCGA as the primary source. This demonstrates the power of using TCGA 
      as a potential resource to develop prognostic tools for improving individualized 
      patient care.
CI  - (c) 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Wong, Nathan
AU  - Wong N
AD  - Department of Radiation Oncology, Washington University School of Medicine, St. 
      Louis, Missouri.
AD  - Department of Biomedical Engineering, Washington University, St. Louis, Missouri.
FAU - Khwaja, Shariq S
AU  - Khwaja SS
AD  - Department of Radiation Oncology, Washington University School of Medicine, St. 
      Louis, Missouri.
FAU - Baker, Callie M
AU  - Baker CM
AD  - Department of Radiation Oncology, Washington University School of Medicine, St. 
      Louis, Missouri.
FAU - Gay, Hiram A
AU  - Gay HA
AD  - Department of Radiation Oncology, Washington University School of Medicine, St. 
      Louis, Missouri.
FAU - Thorstad, Wade L
AU  - Thorstad WL
AD  - Department of Radiation Oncology, Washington University School of Medicine, St. 
      Louis, Missouri.
FAU - Daly, Mackenzie D
AU  - Daly MD
AD  - Department of Radiation Oncology, Washington University School of Medicine, St. 
      Louis, Missouri.
FAU - Lewis, James S Jr
AU  - Lewis JS Jr
AD  - Department of Pathology and Immunology, Washington University School of Medicine, 
      St. Louis, Missouri.
AD  - Department of Pathology, Microbiology and Immunology, Vanderbilt University 
      Medical Center, Nashville, Tennessee.
FAU - Wang, Xiaowei
AU  - Wang X
AD  - Department of Radiation Oncology, Washington University School of Medicine, St. 
      Louis, Missouri.
AD  - Department of Biomedical Engineering, Washington University, St. Louis, Missouri.
LA  - eng
GR  - R01 GM089784/GM/NIGMS NIH HHS/United States
GR  - UL1 TR000448/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20160425
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Carcinoma, Squamous Cell/diagnosis/*genetics/*mortality
MH  - Computational Biology/methods
MH  - Databases, Nucleic Acid
MH  - Female
MH  - Gene Expression Profiling
MH  - Genomics/methods
MH  - Head and Neck Neoplasms/diagnosis/*genetics/*mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Prognosis
MH  - Reproducibility of Results
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - *Transcriptome
PMC - PMC4944889
OTO - NOTNLM
OT  - Gene signature
OT  - The Cancer Genome Atlas
OT  - head and neck cancer
OT  - microRNA
OT  - oropharyngeal cancer
OT  - prognosis
EDAT- 2016/04/26 06:00
MHDA- 2017/11/29 06:00
PMCR- 2016/04/25
CRDT- 2016/04/26 06:00
PHST- 2016/01/12 00:00 [received]
PHST- 2016/02/24 00:00 [revised]
PHST- 2016/03/07 00:00 [accepted]
PHST- 2016/04/26 06:00 [entrez]
PHST- 2016/04/26 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/04/25 00:00 [pmc-release]
AID - CAM4718 [pii]
AID - 10.1002/cam4.718 [doi]
PST - ppublish
SO  - Cancer Med. 2016 Jul;5(7):1619-28. doi: 10.1002/cam4.718. Epub 2016 Apr 25.